hERG potassium channels and the structural basis of drug-induced arrhythmias.
about
In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channelA molecular switch driving inactivation in the cardiac K+ channel HERGCardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancerPyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosisEndocytosis of HERG is clathrin-independent and involves arf6.A k-nearest neighbor classification of hERG K(+) channel blockers.Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndromeKCNH2 pharmacogenomics summary.Drug-induced hERG block and long QT syndrome.Predicting drug-induced QT prolongation and torsades de pointes: a review of preclinical endpoint measures.Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel.New Trends in Cancer Therapy: Targeting Ion Channels and Transporters.Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.Compilation and physicochemical classification analysis of a diverse hERG inhibition database.Automated electrophysiology makes the pace for cardiac ion channel safety screening.Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.Molecular Mechanisms of Crude Oil Developmental Toxicity in Fish.Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men.Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.Trapping and dissociation of propafenone derivatives in HERG channels.hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.Clenbuterol Attenuates hERG Channel by Promoting the Mature Channel Degradation.High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues.Investigating the state dependence of drug binding in hERG channels using a trapped-open channel phenotype.An in Vitro Assay of hERG K + Channel Potency for a New EGFR Inhibitor FHND004.
P2860
Q27311255-66A42A58-5016-42C2-B08E-B84B9E196C40Q28481507-460B3119-7E53-4B4E-B425-1DD70FFCF07FQ34617904-58CACB51-DEC5-40E5-B43C-6E64B08FF8BBQ34779943-551C7012-0326-481D-AA55-13E822C733DFQ35083164-544F7756-6DA8-4DBC-B30B-6A75EB13E52DQ35918516-F978AB68-0C66-476A-8A58-44EFF6C695A7Q36387356-34E18AB8-CB06-43D1-9A6D-6009E56C33DAQ37691207-2DA2F429-7A31-4D67-9FBC-6BFDA5AC4B25Q37734559-C0BFB167-E1C6-47F7-B2B8-8837228AD75EQ38112652-EAECAF73-1A84-45CD-B3A0-95C890A5B7F2Q38304968-BB428B96-55A7-419E-AD4A-D3CE85003561Q38909233-5C374C08-574D-417E-9ED6-BA0B6B93A627Q38974256-1A2FB396-25D7-43F4-B40B-922FBFB9A741Q39233887-50A07F74-5962-4C85-A3DF-00DFE2D1DF74Q39248121-1D0FB1BE-9A3F-4467-80E6-3B0F2A608820Q39331354-A6F707BA-BE41-4119-9111-5B3AADC77F91Q39365157-48F530C4-0A67-435B-A455-11ECBE6D2DABQ39427481-3FEDD4DC-7BC1-4E05-87BA-B72AC735BF0CQ41508156-5E192001-FEF3-433B-92ED-2F68810BCE43Q42173245-A7AA6FBC-E6B4-4489-880A-030F12A22DF6Q42197396-7D91CC6B-FCD9-4E61-A716-D69BE0BD10C2Q45382195-E4892BCE-DD60-4D6E-A222-1AE714888933Q50628884-904D955A-B5BE-4D2A-B410-E738A9FEA49FQ51305938-AB66590A-917B-46B8-B0C8-619722C4EF8DQ53219340-E05B9615-A121-4632-A736-3EF118081B9AQ54942021-9DE2DEC8-1093-4D50-8C8E-13401A2F362BQ55175160-1F9012E7-E5CF-4D71-AB58-36A9ED92745E
P2860
hERG potassium channels and the structural basis of drug-induced arrhythmias.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
hERG potassium channels and the structural basis of drug-induced arrhythmias.
@en
hERG potassium channels and the structural basis of drug-induced arrhythmias.
@nl
type
label
hERG potassium channels and the structural basis of drug-induced arrhythmias.
@en
hERG potassium channels and the structural basis of drug-induced arrhythmias.
@nl
prefLabel
hERG potassium channels and the structural basis of drug-induced arrhythmias.
@en
hERG potassium channels and the structural basis of drug-induced arrhythmias.
@nl
P356
P1476
hERG potassium channels and the structural basis of drug-induced arrhythmias.
@en
P2093
John S Mitcheson
P304
P356
10.1021/TX800035B
P577
2008-05-01T00:00:00Z